The failure rate for tissue plasminogen activator (tPA), a clot-busting drug commonly used to treat ischemic stroke that can be administered at primary stroke centers, is up to 90% for large vessel occlusions (LVOs). This evidence concerns the gene PLAT and stroke disorder.